Lista de obras - Dougald M. Monroe - Dominio Público Uruguay

A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.

artículo científico publicado en 2012

A mouse bleeding model to study oral anticoagulants.

artículo científico publicado en 2014

A novel one-step purification of mouse factor IX.

artículo científico publicado en 2016

A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.

artículo científico publicado en 2009

A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes

artículo científico publicado en 2019

Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.

artículo científico publicado en 2009

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.

artículo científico publicado en 2016

Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces

scientific article published on 01 July 2002

Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells

artículo científico publicado en 2010

Adding some muscle to blood coagulation

artículo científico publicado en 2016

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.

artículo científico publicado en 2016

An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase

artículo científico publicado en 2009

Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.

artículo científico publicado en 2016

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels.

artículo científico publicado en 2013

Celecoxib does not delay cutaneous wound healing in haemophilia B mice

artículo científico publicado en 2009

Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.

artículo científico publicado en 2016

Characterization of the glycosaminoglycan-binding region of lactoferrin

scientific article published on 01 February 1995

Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs

scientific article published on 01 September 2006

Coagulation 2006: a modern view of hemostasis.

artículo científico publicado en 2007

Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations

scientific article published on 01 September 2000

Coated platelet assay: a feasible approach to a complicated science

artículo científico publicado en 2015

Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?

artículo científico publicado en 2015

Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources

artículo científico publicado en 1993

Current concepts of hemostasis: implications for therapy.

artículo científico publicado en 2004

Cutaneous wound healing is impaired in hemophilia B.

artículo científico publicado en 2006

Cystamine preparations exhibit anticoagulant activity

artículo científico publicado en 2015

Deencryption of cellular tissue factor is independent of its cytoplasmic domain.

artículo científico publicado en 2000

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.

scientific article published on 21 January 2014

Dysregulation of hemostasis by cancer.

scientific article published on January 2009

Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies

scientific article published on 29 October 2019

Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk

artículo científico publicado en 2002

Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series

scientific article published on 27 November 2019

FVIIa as used pharmacologically is not TF dependent in hemophilia B mice

artículo científico publicado en 2014

Factor VIIa: on its own and loving it

scientific article published on 01 July 2012

Factor XI promotes hemostasis in factor IX-deficient mice

scientific article published on 16 August 2018

Further understanding of recombinant activated factor VII mode of action.

artículo científico publicado en 2008

Harold Ross Roberts, MD, 1930-2017.

artículo científico publicado en 2017

High dose factor VIIa improves clot structure and stability in a model of haemophilia B.

artículo científico publicado en 2005

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.

artículo científico publicado en 2001

Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system

artículo científico publicado en 2004

In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps.

artículo científico publicado en 2016

In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII.

artículo científico publicado en 2018

Inflammation does not predispose to bleeding in hemophilia

artículo científico publicado en 2010

Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity.

artículo científico publicado en 2012

Major burn injury is not associated with acute traumatic coagulopathy.

artículo científico publicado en 2013

Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia

artículo científico publicado en 2006

Mechanism of action of high-dose factor VIIa: points of agreement and disagreement

artículo científico publicado en 2003

Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia

artículo científico publicado en 2012

Nontoxic irreversible inhibitors of factors IXa, Xa, and thrombin: potential therapeutic agents for the in vivo regulation of thrombin generation and activity

scientific article published on 01 January 1986

Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition.

artículo científico publicado en 2015

Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia

artículo científico publicado en 2007

Plasmin Activation of Glial Cells through Protease-Activated Receptor 1.

artículo científico publicado en 2013

Platelet Heterogeneity

artículo científico publicado en 2005

Platelet activation and its patient-specific consequences

artículo científico publicado en 2007

Platelet activation in patients with thrombotic thrombocytopenic purpura.

artículo científico publicado en 1993

Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.

artículo científico publicado en 2011

Polyphosphates rock! A role in thrombosis?

artículo científico publicado en 2015

Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.

artículo científico publicado en 2012

Progressive improvement in wound healing with increased therapy in haemophilia B mice

artículo científico publicado en 2013

Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

artículo científico publicado en 2016

Protease: Serpin complexes to assess contact system and intrinsic pathway activation

scientific article published on 25 June 2020

Prothrombin times on deficient plasma reconstituted with factors IX and X

scientific article published on 01 November 1994

RNA aptamers as reversible antagonists of coagulation factor IXa.

artículo científico publicado en 2002

Recombinant activated factor VII and the anaesthetist.

artículo científico publicado en 2005

Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.

artículo científico publicado en 2004

Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.

artículo científico publicado en 2007

Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.

artículo científico publicado en 2015

Reversing targeted oral anticoagulants

artículo científico publicado en 2014

Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin

artículo científico publicado en 2004

Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B.

artículo científico publicado en 2016

Soluble phosphatidylserine binds to two sites on human factor IXa in a Ca2+ dependent fashion to specifically regulate structure and activity

artículo científico publicado en 2014

Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.

artículo científico publicado en 1998

Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.

artículo científico publicado en 2012

The Coagulation Cascade in Cirrhosis

artículo científico publicado en 2009

The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients

scientific article published on 01 November 2003

The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis

artículo científico publicado en 2003

The clotting system – a major player in wound healing ⬇️

artículo científico publicado el 1 de julio de 2012

The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking.

artículo científico publicado en 2007

The use of recombinant factor VIIa in the treatment of bleeding disorders.

artículo científico publicado en 2004

Thrombin generation and cell-dependent hypercoagulability in sickle cell disease

artículo científico publicado en 2016

Thrombin generation in vascular tissue.

artículo científico publicado en 2006

Tissue factor around dermal vessels has bound factor VII in the absence of injury

scientific article published on 09 April 2007

Tissue factor in brain is not saturated with factor VIIa: implications for factor VIIa dosing in intracerebral hemorrhage

artículo científico publicado en 2009

VWF (von Willebrand Factor) Is Not Required for Red Blood Cell Retention in Clots in Mice

artículo científico publicado en 2020

Variability in platelet procoagulant activity in healthy volunteers

article

What is wrong with the allosteric disulfide bond hypothesis?

artículo científico publicado en 2009

Wound healing in haemophilia--breaking the vicious cycle.

artículo científico publicado en 2010

Wound healing in hemophilia B mice and low tissue factor mice

artículo científico publicado en 2010

Lista de obras de Dougald M. Monroe

A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.

A mouse bleeding model to study oral anticoagulants.

A novel one-step purification of mouse factor IX.

A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.

A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes

Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.

Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces

Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells

Adding some muscle to blood coagulation

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.

An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase

Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels.

Celecoxib does not delay cutaneous wound healing in haemophilia B mice

Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.

Characterization of the glycosaminoglycan-binding region of lactoferrin

Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs

Coagulation 2006: a modern view of hemostasis.

Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations

Coated platelet assay: a feasible approach to a complicated science

Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?

Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources

Current concepts of hemostasis: implications for therapy.

Cutaneous wound healing is impaired in hemophilia B.

Cystamine preparations exhibit anticoagulant activity

Deencryption of cellular tissue factor is independent of its cytoplasmic domain.

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.

Dysregulation of hemostasis by cancer.

Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies

Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk

Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series

FVIIa as used pharmacologically is not TF dependent in hemophilia B mice

Factor VIIa: on its own and loving it

Factor XI promotes hemostasis in factor IX-deficient mice

Further understanding of recombinant activated factor VII mode of action.

Harold Ross Roberts, MD, 1930-2017.

High dose factor VIIa improves clot structure and stability in a model of haemophilia B.

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.

Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system

In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps.

In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII.

Inflammation does not predispose to bleeding in hemophilia

Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity.

Major burn injury is not associated with acute traumatic coagulopathy.

Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia

Mechanism of action of high-dose factor VIIa: points of agreement and disagreement

Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia

Nontoxic irreversible inhibitors of factors IXa, Xa, and thrombin: potential therapeutic agents for the in vivo regulation of thrombin generation and activity

Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition.

Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia

Plasmin Activation of Glial Cells through Protease-Activated Receptor 1.

Platelet Heterogeneity

Platelet activation and its patient-specific consequences

Platelet activation in patients with thrombotic thrombocytopenic purpura.

Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.

Polyphosphates rock! A role in thrombosis?

Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.

Progressive improvement in wound healing with increased therapy in haemophilia B mice

Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Protease: Serpin complexes to assess contact system and intrinsic pathway activation

Prothrombin times on deficient plasma reconstituted with factors IX and X

RNA aptamers as reversible antagonists of coagulation factor IXa.

Recombinant activated factor VII and the anaesthetist.

Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.

Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.

Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.

Reversing targeted oral anticoagulants

Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin

Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B.

Soluble phosphatidylserine binds to two sites on human factor IXa in a Ca2+ dependent fashion to specifically regulate structure and activity

Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.

Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.

The Coagulation Cascade in Cirrhosis

The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients

The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis

The clotting system – a major player in wound healing ⬇️

The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking.

The use of recombinant factor VIIa in the treatment of bleeding disorders.